Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty

Overview

Información sobre este estudio

The purpose of this study is to determine if peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine will prolong the duration of block, improve pain scores, and decrease opioid utilization in the post-operative period when compared to peripheral nerve block with standard bupivacaine alone.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • All adult patients (>18 years of age).
  • Patients undergoing standard or reverse total shoulder arthroplasty for the primary diagnoses of glenohumeral arthritis or cuff tear arthropathy.
  • Cognitively intact with the ability to give informed consent as outlined by our institutional review board.
  • Patients must be capable of participating in the post-operative electronic survey and / or able to maintain a written diary of events.

Exclusion Criteria

  • Non-elective cases.
  • Infection, tumor, trauma.
  • Weight < 50 kg.
  • Patients with any contraindications to regional anesthesia including allergy or hypersensitivity to amide-type local anesthetics.
  • Patients with allergy to any component of medication regimen e.g. amide-type local anesthetics, oxycodone, hydromorphone, fentanyl.
  • Chronic pain patients with history of chronic opioid use (defined as 20 mg morphine equivalent / day for greater than 30 days pre-operatively.
  • Concurrent painful physical condition that may require analgesic treatment that is not related to the shoulder surgery (chronic peripheral neuropathy, radiculopathy, or other neurologic disorder).
  • Severe hepatic disease defined by elevated liver function tests above normal.
  • Pregnancy.
  • Respiratory disease that contraindicates interscalene nerve block (elevated contralateral hemidiaphragm, contralateral pneumonectomy, or severe COPD with FEV1 < 50% predicted, and 02 dependence).

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Steven Hattrup, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20438545

Mayo Clinic Footer